How etrasimod enters breast milk in healthy breastfeeding women
Treatments studied
This study looks at how the medication etrasimod gets into breast milk after a single dose. If you are a healthy breastfeeding woman at least 12 weeks after giving birth, you may be able to help researchers understand this process. You would need to stop breastfeeding temporarily for 21 days.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy woman who is currently breastfeeding or pumping milk.
- You are at least 12 weeks past childbirth and not pregnant.
- You are between 18 and 55 years old.
- Your body mass index (BMI) is between 16 and 35, and you weigh more than 99 pounds.
- You are willing to stop breastfeeding your baby for 21 days and pump milk on a schedule.
- You do not have any serious health conditions like heart, lung, or liver disease, or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how medicines pass into breastmilk. It helps understand the safety of medications while breastfeeding. If you take medicine and breastfeed, this study may be an option for you.
This study measures how common medicines move through a breastfeeding parent’s milk and checks safety in both the parent and breastfed baby. It may help doctors use these medicines more safely while you continue breastfeeding.
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
This trial studies how medicines you take while breastfeeding get into your breast milk and what that might mean for your baby. It could help you understand if your medication is safe while nursing.
This study looks at how much of the study drug, suzetrigine, gets into breast milk. It helps us understand if it's safe for breastfeeding mothers and their infants.
This study looks at how much BRIUMVI (ublituximab) gets into breast milk. It helps understand if the drug is safe for breastfed babies whose mothers are already taking it for relapsing multiple sclerosis.
Hear when a new Healthy Participant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.